STOCK TITAN

Inhibrx Announces Updated Clinical Data for Ozekibart (INBRX-109) in Ewing Sarcoma

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Inhibrx Biosciences (INBX) reported updated Phase 1/2 Ewing sarcoma data showing a 62.7% overall response rate with its ozekibart combination. Ozekibart was combined with irinotecan and temozolomide in relapsed or refractory disease. At the September 18, 2026 cutoff, 60 patients had been treated, including 9 adolescents; 51 were response-evaluable. Responses included 2 complete and 30 partial responses, while disease control reached 86.3%. Median progression-free survival, the time without disease worsening or death, was 6.0 months (95% confidence interval: 4.6–7.4).

Clinical benefit exceeded 6 months in 18 patients, including one with an ongoing partial response beyond 2 years. Inhibrx described safety as manageable, with no evidence of unexpected cumulative liver toxicity, and plans FDA discussions. Separately, the FDA accepted its application for potential ozekibart approval in conventional chondrosarcoma for filing.

Loading...
Loading translation...
10 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 0 points

Hollow bars mark forward-looking points. How the balance works

Positive

  • Moderate pointOzekibart combination achieved 62.7% overall response rate among 51 evaluable patients: 2 complete and 30 partial responses.
  • Moderate pointFDA accepted for filing the ozekibart biologics license application for potential approval in conventional chondrosarcoma.
  • Minor pointDisease control reached 86.3%, including 12 patients with stable disease.
  • Minor pointTumor size decreased from baseline in 84.3% (43/51) of response-evaluable patients.
  • Minor pointMedian progression-free survival was 6.0 months (95% confidence interval: 4.6–7.4).
5 minor points
  • Minor pointClinical benefit exceeded 6 months in 18 patients: 1 complete response, 1 stable disease, 16 partial responses.
  • Minor pointOne patient's partial response remained ongoing for more than 2 years.
  • Minor pointProgression-free status persisted in 14 response-evaluable patients at cutoff, including 2 exceeding 12 months.
  • Minor pointInhibrx characterized safety as manageable, with no evidence of unexpected cumulative liver toxicity.
  • Minor point. Forward-looking: it has not happened yet and may not happen.Inhibrx plans FDA discussions on the Ewing sarcoma results and intends to advance patient-access plans.

Negative

  • None.

News Explained

Against the historical irinotecan/temozolomide-alone benchmarks cited in the Phase 1/2 Ewing sarcoma update, the combination’s reported 62.7% response rate and 6.0-month median progression-free survival compare with 15%–30% response and roughly 3–4 months, respectively.

Key Figures

Response-evaluable patients: 51 patients Overall response rate: 62.7% (2 complete responses, 30 partial responses) Disease control rate: 86.3% +3 more
Response-evaluable patients
51 patients
Denominator for response results
Overall response rate
62.7% (2 complete responses, 30 partial responses)
Ozekibart plus IRI/TMZ in relapsed or refractory Ewing sarcoma
Disease control rate
86.3%
Ozekibart plus IRI/TMZ
Median progression-free survival
6.0 months (95% CI: 4.6–7.4)
Ozekibart plus IRI/TMZ
Durable clinical benefit
18 patients
Benefit exceeding 6 months
Ongoing partial response duration
More than 2 years
One patient

Previous Clinical trial Reports

1 past event · Latest: Oct 23
Same Type 1 event
  1. Oct 23

    Ewing sarcoma data

    24h Move
    +102.0%

    Interim Ewing data reported 64% ORR, 92% DCR, and one early hepatotoxicity-related fatality.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

overall response rate, disease control rate, progression free survival, biologics license application
4 terms
overall response rate medical
"an overall response rate (ORR) of 62.7%"
Overall response rate is the percentage of patients in a clinical study whose measurable disease shrinks or disappears after receiving a treatment. Investors watch it like a product’s “hit rate” because higher response rates can signal a drug’s effectiveness, boost chances of regulatory approval and market demand, and affect a company’s future revenue prospects, similar to how a higher batting average suggests a more reliable player.
disease control rate medical
"resulting in a Disease Control Rate (DCR) of 86.3%"
The disease control rate is the share of patients in a clinical trial whose cancer or condition either shrinks or stops getting worse for a specified period after treatment. Think of it like the percentage of people for whom a treatment hits pause or nudges back the problem rather than letting it progress; higher rates suggest the therapy can meaningfully limit disease, which matters to investors assessing a drug’s potential efficacy and commercial value.
progression free survival medical
"The median progression free survival (mPFS) was 6.0 months"
Progression free survival is the length of time during and after a treatment when a disease, such as cancer, does not get worse or spread. It is an important measure because longer periods of stability can indicate that a treatment is effectively controlling the condition. For investors, it provides insight into the potential durability and success of a therapy or medication.
biologics license application regulatory
"The FDA accepted for filing our biologics license application"
A biologics license application is a formal request submitted to regulatory authorities seeking approval to market a new biological medicine, such as vaccines or treatments made from living organisms. It is a comprehensive review process that evaluates the safety, effectiveness, and manufacturing quality of the product. For investors, receiving approval signals that a biological therapy can be sold to the public, potentially leading to revenue growth and market success.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

- Ozekibart combination in relapsed/refractory Ewing sarcoma achieves 62.7% ORR;
- 86.3% DCR, with durable responses observed in heavily pretreated patients

SAN DIEGO, Nov. 17, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing novel biologic therapeutic candidates, today announced updated clinical data from the Phase 1/2 expansion study evaluating ozekibart (INBRX-109), an investigational tetravalent death receptor 5 (DR5) agonist, in combination with irinotecan and temozolomide (IRI/TMZ) in patients with relapsed or refractory Ewing sarcoma. The data will be presented at the Connective Tissue Oncology Society (CTOS) 2026 Annual Meeting.

Inhibrx, Inc. logo

"The updated clinical data to be presented at CTOS underscore the deep activity and expanding reach of ozekibart in aggressive, difficult-to-treat bone and soft tissue sarcomas," said Mark Lappe, Chief Executive Officer of Inhibrx. "In relapsed or refractory Ewing sarcoma, achieving a 62.7% overall response rate, an 86.3% disease control rate, and clinically meaningful durability is particularly compelling in a population that has exhausted effective options. Based on these results, we intend to rapidly advance our plans with the goal of allowing patients access as soon as possible."

Ewing Sarcoma

As of the September 18, 2026, data cutoff, 60 patients (including 9 adolescent patients) were enrolled and treated with ozekibart plus IRI/TMZ, with 22 patients remaining on active treatment. Among the 51 response-evaluable patients, the combination demonstrated an overall response rate (ORR) of 62.7%, comprising 2 complete responses (CRs) and 30 partial responses (PRs). A total of 84.3% of response-evaluable patients (43/51) experienced measurable reduction in tumor size from baseline. An additional 12 patients achieved stable disease (SD), resulting in a Disease Control Rate (DCR) of 86.3%.

The median progression free survival (mPFS) was 6.0 months (95% CI: 4.6–7.4). Durable clinical benefit exceeding 6 months was observed in 18 patients (1 CR, 1 SD, 16 PRs), including 1 patient maintaining an ongoing PR for more than 2 years. At the cutoff date, 14 response-evaluable patients remained progression-free, including 2 patients with a PFS duration exceeding 12 months.

These data represent a meaningful improvement over historical benchmarks, such as irinotecan and temozolomide alone in relapsed or refractory Ewing sarcoma, which typically yield an ORR of approximately 15% to 30% and a mPFS of roughly 3 to 4 months.

The combination continued to demonstrate an acceptable and manageable safety profile consistent with the known cytotoxic toxicities of IRI/TMZ and DR5 agonism, with no evidence of unexpected cumulative hepatotoxicity.

The FDA accepted for filing our biologics license application for the potential approval of ozekibart in conventional chondrosarcoma. With approximately 300 new cases of Ewing sarcoma diagnosed each year in the U.S. and an estimated 2,500 individuals in the U.S. currently living with Ewing sarcoma, the need for novel therapeutic options in this underserved community is profound, and we look forward to discussing these results with the FDA.

Presentation Materials

Ewing Sarcoma Poster Details:

  • Title: Phase 1/2 Study of the Tetravalent Death Receptor 5 (DR5) Agonist Ozekibart (INBRX-109) Combined with Irinotecan (I) and Temozolomide (T) in Adolescents and Adults with Ewing Sarcoma (EWS)
  • Session: Poster Presentation Session
  • Abstract Number: 2465416
  • Presenter: Varun Monga, M.D.
  • Date: Thursday, November 19, 2026

The poster materials will be made available in the "Events & Presentations" section of the Inhibrx Biosciences investor portal at inhibrxbiosciences.investorroom.com.

About ozekibart (INBRX-109)

Ozekibart is a precision-engineered, tetravalent death receptor 5 (DR5) agonist antibody designed to exploit the tumor-biased cell death induced by DR5 activation. Ozekibart is engineered to optimize tumor-biased receptor clustering and activation without requiring secondary crosslinking, avoiding the severe hepatotoxicity observed with first-generation DR5-targeting agents.

About Inhibrx Biosciences, Inc.

Inhibrx is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates. Inhibrx utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary protein engineering platforms. Inhibrx's current clinical pipeline of therapeutic candidates includes ozekibart and ordastobart (INBRX-106), both of which utilize multivalent formats where the precise valency can be optimized in a target-centric way to mediate what Inhibrx believes to be the most appropriate agonist function. For more information, please visit www.inhibrx.com.

Forward-Looking Statements

Inhibrx cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on Inhibrx's current beliefs and expectations. These forward-looking statements include, but are not limited to, statements regarding: Inhibrx's judgments and beliefs regarding the strength of Inhibrx's pipeline; statements regarding the safety and efficacy of its therapeutic candidate, ozekibart, based on topline and interim results; the potential for ozekibart to be used for the treatment of Ewing sarcoma and solid tumor indications; the clinical development of ozekibart, including data readouts, regulatory submissions and interactions, and the timing thereof; the potential commercial development of ozekibart; the potential approval by the FDA of ozekibart in unresectable or metastatic conventional chondrosarcoma; and any presumption that topline, interim or preliminary data will be representative of final data or data in later clinical trials. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Inhibrx's business, including, without limitation, risks and uncertainties regarding: topline data may not accurately reflect the complete results of a particular study or trial and remain subject to audit, and final data may differ materially from topline data; the initiation, timing, progress and results of its preclinical studies and clinical trials, and its research and development programs; its ability to advance therapeutic candidates into, and successfully complete, clinical trials; its interpretation of topline, interim or preliminary data from its clinical trials, including interpretations regarding disease control and disease response; results from preclinical studies or early clinical trials not necessarily being predictive of future results; unexpected adverse side effects or inadequate efficacy of its therapeutic candidates that may limit their development, regulatory approval and/or commercialization; the potential for its programs and prospects to be negatively impacted by developments relating to its competitors, including the results of studies or regulatory determinations relating to its competitors; the timing or likelihood of regulatory filings and approvals and regulatory developments in the U.S. and foreign countries; the successful commercialization of its therapeutic candidates, if approved; an accelerated development or approval pathway may not be available for ozekibart or other therapeutic candidates and any such pathway may not lead to a faster development process; the pricing, coverage and reimbursement of its therapeutic candidates, if approved; its ability to utilize its technology platform to generate and advance additional therapeutic candidates; and other risks described from time to time in the "Risk Factors" section of its filings with the U.S. Securities and Exchange Commission, including those described in its Annual Report on Form 10-K, its Quarterly Reports on Form 10-Q, and supplemented from time to time by its Current Reports on Form 8-K as filed from time to time. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Inhibrx undertakes no obligation to update these statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Investor and Media Contact:

Kelly Deck, CFO
ir@inhibrx.com
858-795-4260

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/inhibrx-announces-updated-clinical-data-for-ozekibart-inbrx-109-in-ewing-sarcoma-302942893.html

SOURCE Inhibrx Biosciences, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Inhibrx's ozekibart combination show in Ewing sarcoma?

Ozekibart plus irinotecan and temozolomide achieved a 62.7% overall response rate among 51 response-evaluable patients with relapsed or refractory Ewing sarcoma. There were 2 complete responses and 30 partial responses. Disease control reached 86.3%, and median progression-free survival was 6.0 months.

How does Inhibrx compare the ozekibart Ewing sarcoma results with historical chemotherapy results?

Inhibrx describes the results as an improvement over historical irinotecan and temozolomide benchmarks of approximately 15% to 30% overall response and roughly 3 to 4 months median progression-free survival. The updated ozekibart combination results were 62.7% and 6.0 months, respectively; the comparison is historical rather than a reported concurrent control arm.

How many patients were still receiving Inhibrx's ozekibart combination at the Ewing sarcoma data cutoff?

22 patients remained on active treatment at the September 18, 2026 cutoff. Overall, 60 patients, including 9 adolescents, had enrolled and received ozekibart plus irinotecan and temozolomide.

Keep reading